InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.040 -0.015 (-27.27%)+
Announcement
Release
25 Feb 2026 9:29AM
Price at Release
$0.055
Full Release
download
Summary
Argent Biopharma Limited announced the filing of a U.S. provisional patent for its NanoBodies platform, which targets vascular and peptide-mediated mechanisms implicated in septic shock and systemic inflammatory disorders. The NanoBodies programme, aimed at extending the company's immune-modulatory portfolio, focuses on upstream signalling control in immune responses. This development secures priority protection and offers a 12-month period to further develop the platform. NanoBodies, known for their structural stability and enhanced tissue accessibility, are positioned to address complex immune processes, complementing the company's existing pipeline that targets cytokine pathways. The platform's integration into Argent's Neuro-Immune strategy signifies a strategic expansion in addressing inflammatory disorders.
Key Points
  • Provisional patent application filed with USPTO for NanoBodies platform.
  • NanoBodies target septic shock and systemic inflammatory disorders.
  • The initiative expands immune-modulatory portfolio beyond cytokine regulation.
  • NanoBodies offer structural stability and enhanced tissue accessibility.
  • Proof-of-concept studies planned using septic shock model.
  • The platform reinforces Argent BioPharma’s Neuro-Immune strategy.
  • Commercial milestone strengthens U.S.-centred intellectual property position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.